Search
Louisiana Paid Clinical Trials
A listing of 887 clinical trials in Louisiana actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
697 - 708 of 887
Louisiana is currently home to 887 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Effect of Pulsatile Hormone Administration on Insulin Action
Recruiting
In humans, insulin is secreted in pulses from the pancreatic beta-cells, and these oscillations help to maintain fasting plasma glucose levels within a narrow normal range. Given the fluctuations in insulin concentrations, oscillations enhance precision of control. The hyperinsulinemic euglycemic clamp test (clamp) involves a continuous infusion of insulin and is the gold standard for measuring insulin sensitivity. In this study, insulin sensitivity measured using the standard clamp will be comp... Read More
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
01/14/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Insulin Sensitivity
Safety Aid Reduction Treatment for PTSD Among Veterans
Recruiting
The purpose of this project is to examine the acceptability, feasibility, and utility of a safety aid reduction treatment (START) among Veterans with posttraumatic stress disorder (PTSD). It is hypothesized that START will be acceptable, feasible, and will lead to reductions in PTSD symptom severity immediately and over time.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Southeast Louisiana Veterans Health Care System, New Orleans, LA, New Orleans, Louisiana
Conditions: Stress Disorders, Post-Traumatic
Von Willebrand Factor in Pregnancy (VIP) Study
Recruiting
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding.
This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum peri... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders, New Orleans, Louisiana
Conditions: Von Willebrand Diseases
Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain
Recruiting
The goal of this randomized control clinical trial is to learn if virtual reality can be used to treat sickle cell pain in children. The main questions it aims to answer are:
Does virtual reality reduce pain severity during a child's hospital stay for a vaso-occlusive pain crisis?
Does virtual reality decrease the daily use of opiates?
Researchers will compare standard therapy to the use of standard therapy plus a daily virtual reality experience to see if virtual reality works to treat sickl... Read More
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
01/13/2025
Locations: Children's Hospital of New Orleans, New Orleans, Louisiana
Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episodes
The Hyalex Early Feasibility Study (EFS)
Recruiting
The Hyalex Early Feasibility Study is a prospective, multicenter, open-label, single-arm, 2-phase early feasibility study to evaluate the safety and technical performance of the HYALEX Knee Cartilage System for replacement of loss of articular cartilage and bone of the knee femoral condyles in symptomatic patients who require surgical treatment, will be enrolled in the study and undergo implantation of the HYALEX Knee Implant.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
01/13/2025
Locations: Ochsner Sports Medicine Institute, New Orleans, Louisiana
Conditions: Cartilage Injury, Cartilage Damage
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
01/10/2025
Locations: Louisiana State University Health Sciences Center- New Orleans, New Orleans, Louisiana
Conditions: Breast Cancer
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: East Jefferson General Hospital, Metairie, Louisiana
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Randomized Clinical Trial of Re-Evaluating Suicidal Thoughts in Veterans
Recruiting
Suicide prevention is a top priority for VA as all continue to seek new and inventive ways to reduce suicide rates among Veterans. Many experts agree that suicide prevention efforts could be improved by making suicide-specific interventions easier to access. The current project aims to move toward that goal by testing a web-based suicide prevention intervention using an experimental design. The roughly 40-minute intervention aims to teach Veterans coping skills that are designed to ease the emot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Southeast Louisiana Veterans Health Care System, New Orleans, LA, New Orleans, Louisiana
Conditions: Suicidal Ideation, Suicide, Attempted
Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae
Recruiting
This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter in subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Ochsner Health System, New Orleans, Louisiana
Conditions: Arteriovenous Fistula
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Recruiting
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Louisiana State University, New Orleans, Louisiana
Conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology
Recruiting
This is a phase 0, non-interventional, longitudinal, electronic data capture (EDC) study to facilitate the HEARTBEAT Study project has set out to explore the potential use of smartwatches in collecting and analyzing biometric data to improve the detection, identification, and understanding of cardiovascular diseases and related conditions by SAMSUNG and Tulane. The study will include up to ten thousand adult subjects tasked with wearing a smartwatch to collect digital biomarker data over a 1 yea... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/02/2025
Locations: East Jefferson General Hospital, New Orleans, Louisiana
Conditions: Heart Diseases
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Recruiting
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana
Conditions: HNSCC